Pfizer Settles in Celebrex Investor Lawsuit

Pfizer Inc. has decided to pay $164 million to settle a shareholder class action consumer fraud lawsuit that alleged that the company misled investors about clinical trial results for its arthritis drug Celebrex.

Reuters reports that the world’s largest pharmaceutical company denies any wrongdoing in the matter. The settlement was unveiled — just two weeks before the company was to go to trial — in court papers filed on October 6th in a New Jersey district court.

If you or a loved one has been harmed by a consumer fraud, contact Sokolove Law today for a free legal consultation and to find out if a consumer fraud lawyer may be able to help you.

Tags: